IPO
Led by ARTIS Ventures, Funding will Drive Further Research and Commercialization of Eko’s Machine Learning Platform
Summit Therapeutics plc announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.
Company inaugurates its new production unit for active pharmaceutical ingredients, the cornerstone of Provepharm’s development
H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc that Amphion has agreed to amend the terms of the Loan Facility with Amphion’s debt provider.
Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.
Tacalyx announced that it has successfully secured €7 million in seed funding.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
Catalyst Pharmaceuticals, Inc., is commenting on trading activity in its common stock and on the current state of its capital resources.
PRESS RELEASES